I-Mei (Emay) Siu
@imsmd
Senior Editor at Cancer Discovery @CD_AACR and cancer biologist (aka @[email protected]): views are most certainly my own
Our collaboration with @samuels_yardena and @NCIEytanRuppin is out in @CD_AACR ! Why do genetically similar tumors show dramatic differences in immune rejection? We used temporal single-cell genomics of rejection + CRISPR screens to identify a potential cause related to…
Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in #Melanoma - by Sapir Cohen Shvefel, @joyp_ai, @NCIEytanRuppin, @Satpathology, @samuels_yardena, and colleagues doi.org/10.1158/2159-8… @stanfordimmuno @WeizmannScience
Andrew Aguirre discusses potential KRASi combinations with other modalities including immunotherapy for PDAC and cites a recent paper by @RonDePinho and colleagues as an example 👉🏻 aacrjournals.org/cancerdiscover…
Amazing: 2 patients spontaneously shared their incredible journeys at @theNCI Clinical Center, one of whom was a patient of Steven Rosenberg, and @NCIDirector emphasized the crucial role of basic-clinical crosstalk in helping patients, as exemplified by Steven Rosenberg
👏🏻👏🏻👏🏻
Thrilled to share that our new paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in melanoma, is now published in @Cancer Discovery! Find the full study here: aacrjournals.org/cancerdiscover…
Jillian Phalen @hopkinskimmel presenting just-published work on DELFI (cell-free fragmentome/proteins) for the early detection of ovarian cancer #aacrLBx24 aacrjournals.org/cancerdiscover…
Excited to be here! If you’re here and want to ask about @CD_AACR, come join me for breakfast 🥞
Senior Editor I-Mei Sui, PhD is at the @AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation. #aacrLBx24 Connect with her before or after the meeting to discuss your research and publishing opportunities! @imsmd
Senior Editor I-Mei Sui, PhD is at the @AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation. #aacrLBx24 Connect with her before or after the meeting to discuss your research and publishing opportunities! @imsmd
Excited to share our new paper out in @CD_AACR! We developed GCOs—glioblastoma cells grown in human cortical organoids—and used scRNA-seq to show their increased fidelity to patient cell states. Plus, we found tumor cells transfer malignant mRNAs to non-malignant cells!
Now online in @CD_AACR: #Glioblastoma-Cortical #Organoids Recapitulate Cell State Heterogeneity and Intercellular Transfer - by Vamsi Mangena, @RChanoch, Paola Arlotta, @tiroshlab, @MarioSuva, & colleagues doi.org/10.1158/2159-8… @broadinstitute @weizmannscience @MGHCancerCenter
It’s the final day of @theNCI #RAS Initiative, and for the first time there is a pediatric cancer-focused session: there is a growing body of literature on Ras in pediatric cancer, as Elliot Steiglitz @UCSFCancer shows 👉🏻 aacrjournals.org/cancerdiscover…
Andy Stephen @FredNatLab is speaking at @theNCI #RAS Initiative about the allosteric regulation of SOS, including the evaluation of the REM domain: since pictures are strictly forbidden, here is a completely accurate depiction of said domain 👉🏻
Day 2 of @theNCI #RAS Initiative kicks off with @AACR_CEO giving an overview of the close relationship between @AACR and the #RAS community as well as the goals and vision that the @AACR has for promoting advances in this community
Robert Vonderheide @PennCancer suggests that KRAS inhibitors are immunotherapies and describes the work describing the effects of KRASi on the tumor immune contexture that Ben Stanger, he, and colleagues published last year 👉🏻 aacrjournals.org/cancerdiscover…
Mallika Singh of @Rev_Medicine is describing the strategy used to generate exciting pan-RAS RevMed inhibitors: check out the preclinical evaluation and characterization of RMC-6236 (includes patient data!) 👉🏻 aacrjournals.org/cancerdiscover…
Andrew Aguirre @DanaFarber is speaking about the identification of RAS G12C inhibitor resistance mechanisms at @theNCI #RAS Initiative Symposium, including work he and colleagues recently published 👉🏻 aacrjournals.org/cancerdiscover…
The Fifth @theNCI #RAS Initiative Symposium (and my third!) is starting with @NCIDirector starting things off with her thoughts on the importance of the RAS Initiative in fostering collaborations/inspiration: also, she’s going to stay for the first day, so meet her if you can!
Excited to attend the inaugural @AACR Grantee Summit to hear about the exciting work of AACR grantees and participate in a roundtable discussion on how to publish papers! Did you know that AACR has funded over $500 million of research grants over the past 30 years? #AACRgrants
Thrilled to introduce "The Epigenetic Hallmarks of Cancer", our Cancer Discovery @CD_AACR @AACR article. A team work by Mark Dawson @MAF_Dawson, Cigall Kadoch @CKadoch, Feyruz Rassool, Peter Jones, Steve Baylin and yours truly. Enjoy! aacrjournals.org/cancerdiscover…
I had the honor of presenting @NCIResearchCtr’s Dr. Steven Rosenberg with a milestone award for 50 years of excellent service to @theNCI. His pioneering work in immunotherapy has touched lives, inspired researchers, and transformed our field. Congratulations, Steven!
The 2nd day of @theNCI symposium celebrating Steven Rosenberg is off to a strong start ✨on a side note, a @CD_AACR paper by the Rosenberg group has been cited these 2 days, so here it is 😊👉🏻 aacrjournals.org/cancerdiscover…